Laparoscopic Gastric Bypass as Metabolic Surgery in Obesity Class 1

Gastric Bypass as Metabolic Surgery in Obesity Class 1: a Prospective Study of the Short, Mid and Long Term Results Among Mexicans

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04595396

Enrollment

Registered

2020-10-20

Start date

2012-09-01

Completion date

2019-12-31

Last updated

2020-10-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bariatric Surgery Candidate, Laparoscopic Gastric Bypass, Obesity, Type2 Diabetes

Keywords

bariatric surgery, obesity class 1, metabolic surgery, laparoscopic gastric bypass, type-2 diabetes mellitus

Brief summary

Prospective study including Mexican patients diagnosed with type 2 diabetes and class 1 obesity, undergoing laparoscopic gastric bypass. The objective was to determine short, mid-and long-term outcomes (weight loss, metabolic, morbidity and diabetes remission). A subanalysis was included, based on preoperative usage of one (Group A) or more antidiabetics ± insulin (Group B).

Interventions

PROCEDURELaparoscopic Gastric Bypass

The LGBP was performed using a classic Roux-en-Y procedure. Briefly, a gastric pouch of 30-50 cc was constructed with an antecolic calibrated gastro-jejunal anastomosis (mechanical anastomosis using a 2.5 mm load). The biliary and alimentary limbs measured ≈70 cm and ≈150 cm, respectively, and the jejuno-jejunal anastomosis was also performed in a latero-lateral fashion (mechanical anastomosis using a 2.5 mm load). Mesenteric defects were closed with running non-absorbable sutures and the omentum was divided in every case

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Inclusion criteria

Any sex \>18 years-old \<60 years-old Class 1 obesity (BMI 30-34.9 kg/m2) Type-2 diabetes mellitus diagnosis (with or without medication) Submitted to laparoscopic gastric bypass

Exclusion criteria

Other bariatric surgery Revisional surgery Incomplete charts

Design outcomes

Primary

Measure	Time frame	Description
Weight Loss	12 months	Measure: weight (kilograms)

Secondary

Measure	Time frame	Description
Complete Diabetes Remission	12 months	Definition: no antidiabetic drugs while on glucose \<100 mg/dl and HbA1C% \<6
Late complications	After 30 days from surgery	Complications requiring re-admssion / re-operation
Early complications	First 30 days after surgery	Complications requiring re-admssion / re-operation

Countries

Mexico

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 24, 2026